Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at support@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support support@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support support@hstalks.com
We hope you have enjoyed this limited-length demo talk
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Diabetes complications
- Coronary artery disease mortality in type 1 diabetes
- Cardiovascular disease mortality in type 1 diabetes
- Life expectancy with type 1 diabetes
- Cause-specific death in type 1 diabetes
- Preventing complications in type 1 diabetes
- Diabetes control and complications trial
- Diabetes control and complications trial follow-up
- Intensive T1D treatment and cardiovascular events
- DCCT cumulative mortality by treatment group
- Preventing complications - DCCT
- Excellent vs. poor T1D control
- Glycaemic control survey across Europe
- Insulin pump treatment risks and benefits
- Preventing complications in T1D - other risk factors
- Statins in type 1 diabetes
- Preventing complications in T1D - HPS
- Obesity in type 1 diabetes
- Obesity in type 1 diabetes - Scottish survey
- Insulin resistance in type 1 diabetes
- Metformin and endothelial function
- Systematic review: metformin in type 1 diabetes
- Metformin and the AMPK enzyme
- Metformin suppresses gluconeogenesis
- Preventing complications in T1D REMOVAL trial
- The REMOVAL trial design
- REMOVAL trial world distribution
- REMOVAL trial recruitment and measurements
- Carotid IMT as an outcome measure in T1D
- The glucagonocentric restructuring of diabetes
- Preventing complications in T1D - GLP-1
- GLP-1 agonists
- GLP-1 modes of action in humans
- GLP-1 receptor agonists in T2DM
- GLP-1 receptor agonists in T2DM - weight change
- GLP-1 agonists and blood pressure meta analyses
- GLP-1 agonist trials in T2DM
- GLP-1 trials in T1DM
- Preventing complication in T1D - DPP-4
- DPP-4 inhibitors
- Preventing complication in T1D - SGLT2
- SGLT2 inhibitors
- SGLT2 inhibitors mechanism of action
- SGLT2 inhibitors - blood pressure effect
- Glucose control with SGLT2 inhibitors
- Weight change with SGLT2 inhibitors
- SGLT2 inhibitor trials in T2DM
- SGLT2 inhibitor trials in T1DM
- Preventing complications in T1D - adjunct therapies
- The RENEWAL trial
- Preventing complications: Intermediate mechanisms
- Conclusions
- Acknowledgments
- Potential conflicts of interest
Topics Covered
- Type 1 diabetes and reduction in life expectancy
- Tight glycaemic control and reduction of complications
- Intensive insulin therapy association with hypoglycaemia and weight gain
- “Non-insulin adjunct therapy” and relevant clinical trials
Links
Series:
Categories:
- Biochemistry
- Cell Biology
- Clinical Medicine
- Diseases, Disorders & Treatments
- Metabolism & Nutrition
- Pharmaceutical Sciences
Therapeutic Areas:
Talk Citation
Petrie, J. (2015, August 31). Type 1 diabetes: control and complications trials [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 23, 2019, from https://hstalks.com/bs/3101/.Publication History
Type 1 diabetes: control and complications trials
Published on August 31, 2015
44 min
Other Talks in the Series: Diabetes in Perspective
Transcript
0:00
JOHN PETRIE: I'm John Petrie.
I'm professor of diabetic
medicine at the University
of Glasgow in the UK.
This presentation is
about Type 1 Diabetes,
Control and Complications Trials.
0:13
The complications of diabetes
that have been established
over many years are shown on the
left-hand side of this slide,
and the more recently recognized
ones are on the right.
The complications that we
will be focusing on today
are those of myocardial
infarction and stroke,
sometimes known as the
macrovascular complications,
which can also include
peripheral vascular disease.
0:41
The slide here shows a study by
Krolewski, which compared the rates
of mortality in the Pittsburgh
cohort of people with type 1
diabetes, with those in
the Framingham cohort,
looking at mortality over
different age groups.
And from this slide,
published in 1987,
you can see that the rates of
mortality in people with type 1
diabetes were very high.
And this was mainly due to coronary
artery disease in comparison
with non-diabetic,
healthy individuals
in the Framingham cohort.
This is a case in men and women.
And the relative risk of
mortality at any particular age,
you'll see in this slide, is
really massively elevated up
to 20-fold in some age groups, and
particularly high in young women
in whom the background
rates in the population
are, of course, very low.